Abstract

 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses mavacamten (Camzyos), 2.5 mg, 5 mg, 10 mg, and 15 mg oral capsules.
 Indication: For the treatment of symptomatic obstructive hypertrophic cardiomyopathy of New York Heart Association class II to III in adult patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have